RT Journal Article
T1 CON: Carbapenems are NOT necessary for all infections caused by ceftriaxone-resistant Enterobacterales
A1 Rodriguez-Bano, Jesus
A1 Gutierrez-Gutierrez, Belen
A1 Pascual, Alvaro
K1 Blood-stream infections
K1 Escherichia-coli
K1 Piperacillin-tazobactam
K1 Klebsiella-pneumoniae
K1 Efficacy
K1 Antibiotics
K1 Safety
AB Carbapenems are considered the drugs of choice for the treatment of serious infections caused by ceftriaxoneresistant Enterobacterales. However, because of the dramatic increase in carbapenem-resistant organisms worldwide, finding alternatives to carbapenems is a must. The potential options include beta-lactam/beta-lactamase inhibitor combinations, temocillin, cephamycins and some non-beta-lactamdrugs. The most controversial is piperacillin/tazobactam; the results of the MERINO trial are challenged because the isolates of patients with worse outcomes were frequently not susceptible to piperacillin/tazobactam when studied by reference methods, and also because the drug was not administered in extended infusion. Other potential options are briefly discussed. We conclude that carbapenems are not necessary for all patients with infections caused by ceftriaxone-resistant Enterobacterales.
PB Oxford univ press
YR 2021
FD 2021-02-23
LK https://hdl.handle.net/10668/27973
UL https://hdl.handle.net/10668/27973
LA en
DS RISalud
RD Apr 6, 2025